Dr. Shaun Setty Is Appointed CMO of HD Medical

Dr. Shaun Setty is a cardiothoracic surgeon in Los Angeles, CA, with over 13 years of experience in pediatric and adult congenital cardiac surgery.

Dr. Shaun Setty is triple-board certified in surgery, thoracic surgery, and congenital heart surgery, with experience in all aspects of cardiac surgery.

Dr. Setty began his medical education at the Medical College of Ohio, where he graduated with Alpha Omega Alpha honors, followed by a general surgery residency at Oregon Health & Science University. He went on to complete his cardiothoracic surgery training at the University of Minnesota/Lillehei Heart Institute, the birthplace of modern cardiac surgery.

Dr. Setty continued on to do his congenital cardiac surgery fellowship at the renowned Royal Children’s Hospital in Melbourne, Australia, and spent a year at Green Lane Hospital in New Zealand as a pediatric and adult cardiac surgery fellow. He also has experience in robotic and transplant surgery and is currently involved in multiple basic and clinical cardiac research projects.

Setty was integral in the launch of HD Medical’s flagship product, HD Steth. HD Steth is the first of its kind FDA Cleared Intelligent Stethoscope with ECG and PCG in a single device. This simple-to-use tool has a familiar stethoscope form factor and workflow that enables clinicians, hospitals, and telehealth providers to capture, record, replay, and visualize heart sounds and ECG waveforms instantaneously on the HD Steth Android or Apple iOS app.

The HD Steth app delivers superior ECG waveforms with the ability to detect high-frequency heart sounds indicative of murmurs. Medical professionals now have access to patented algorithms and high-definition visualization, in addition to noise-cancellation technologies that support an instantaneous diagnosis by a remote specialist.

“I’m excited to join HD Medical at this critical time in their growth,” says Dr. Shaun Setty. “With HD Steth rising in popularity plus the introduction of our new HealthyU all-in-one remote patient monitor at CES in January, I believe HD Medical is well-positioned to be a leader in the stethoscope and remote monitoring space.”

The input and overall direction from Dr. Setty will aid in the continued development and growth of HD Medical as a whole,” says Arvind Thiagarajan, founder and CEO of HD Medical. “Dr. Setty has proven to be an invaluable advisor, and we are thrilled to welcome him as our new CMO. Additionally, his clinical vision will continue to drive our mission to save lives through early detection of CVD.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”